ReviewToxins2019
Fumagillin, a Mycotoxin of
Review in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 101 citations in OpenAlex.
- HosA-mediated epigenetic regulation of growth, virulence, and secondary metabolism inVirulence · 2026Article
- Secondary Metabolites from the Marine-Derived Fungus Aspergillus udagawae SFC20170619-M03 Exhibiting Disease Control Activity.The plant pathology journal · 2026Article
- Epidemiological and Metabolic Characteristics ofAnimals : an open access journal from MDPI · 2026Article
- Temperature duringbioRxiv : the preprint server for biology · 2026Article
- Editing gliA, gliP and gliZ of Aspergillus fumigatus Using CRISPR/Cas System Renders Fungus Incapable to Produce Gliotoxin.Molecular biotechnology · 2026Article
- Encephalitozoonosis in Pet Rabbits: Epidemiology, Pathogenesis, Immunology and Consensus on Clinical Management.Animals : an open access journal from MDPI · 2026Review
- A network-based model of Aspergillus fumigatus elucidates regulators of development and defensive natural products of an opportunistic pathogen.Nucleic acids research · 2026Article
- Repositioning Antimicrobial Peptides Against WHO-Priority Fungi.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Regulation and induction of fungal secondary metabolites: a comprehensive review.Archives of microbiology · 2025Review
- Review
- Machine Learning-Based Bioactivity Classification of Natural Products Using LC-MS/MS Metabolomics.Journal of natural products · 2025Article
- Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections.Current drug targets · 2025Review
- DNA metabarcoding uncovers fungal communities inChinese herbal medicines · 2024Article
- Review
- Endophytic fungi: A future prospect for breast cancer therapeutics and drug development.Heliyon · 2024Review
- Managing Microbiota Activity ofMicroorganisms · 2024Article
- Fungal profile, levels of aflatoxin M1, exposure, and the risk characterization of local cheese 'Toxicology reports · 2024Article
- Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity.Molecular cancer therapeutics · 2024Article
- Universal signatures of transposable element compartmentalization across eukaryotic genomes.bioRxiv : the preprint server for biology · 2024Article
- Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fumagillin is a mycotoxin produced, above all, by the saprophytic filamentous fungus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.